Hypogonadotropic Hypogonadism in a 22-Year-Old Male

The Clinical Picture

Part 1: Physiology of Testosterone and Its Release

The HPG Axis (Goldman-Cecil Medicine, Fig. 216-1)

• LH — acts on Leydig cells (interstitial) → stimulates testosterone synthesis via cholesterol side-chain cleavage (StAR protein, P450scc → pregnenolone → DHEA → androstenedione → testosterone)
• FSH — acts on Sertoli cells → stimulates spermatogenesis and inhibin B secretion

• Leydig cells synthesize testosterone from cholesterol. Normal serum testosterone: 264–916 ng/dL in men aged 19–39.
• Testosterone undergoes peripheral conversion: to dihydrotestosterone (DHT) via 5α-reductase (responsible for prostate growth, male pattern baldness, external genital virilization), and to estradiol (E2) via aromatase (responsible for bone closure, libido modulation).
• Sertoli cells, under FSH and high intratesticular testosterone, produce inhibin B and support spermatogenesis. Inhibin B feeds back to suppress FSH.

• Testosterone and estradiol exert long-loop negative feedback on both hypothalamus and pituitary — suppressing GnRH pulse frequency and LH/FSH amplitude.
• A strong diurnal rhythm exists: testosterone peaks in the morning (before 10 AM), hence the clinical importance of morning blood draws. — Goldman-Cecil Medicine, p. 2539

• Androgenic: secondary sexual characteristics (beard, body hair, phallus, scrotum), voice deepening, libido, sexual function
• Anabolic: skeletal muscle growth, erythropoiesis (EPO stimulation), bone density
• Via DHT: external genitalia development, prostate, sebaceous glands, androgenic alopecia
• Via E2 (aromatization): bone maturation, epiphyseal fusion, some aspects of libido and sexual function

Part 2: Diagnosis

Most Likely Diagnosis: Hypogonadotropic Hypogonadism (Secondary Hypogonadism)

Why?

Differential within HH:

1. Congenital HH (Kallmann syndrome or normosmic idiopathic HH) — most likely here given young age, no systemic disease, incomplete puberty. Kallmann syndrome adds anosmia (absent GnRH neurons fail to migrate from olfactory placode). FGFR1, GNRH1, PROKR2 gene mutations are the most common.
2. Functional HH — from chronic illness, starvation, anorexia, excessive exercise, opioid use
3. Pituitary tumor (e.g., prolactinoma — check for visual field defects, galactorrhea, and headache)
4. Infiltrative disease (hemochromatosis, sarcoidosis)

Diagnostic workup:

1. Morning serum total testosterone (×2, before 10 AM) — confirm low level (<264 ng/dL; treatment indicated if consistently <230 ng/dL with symptoms)
2. Serum LH and FSH — will be low/inappropriately normal (not elevated as in primary hypogonadism) — this is the key distinguishing lab
3. Serum prolactin — mandatory in all HH to exclude prolactinoma
4. MRI pituitary — to exclude structural lesion
5. Serum FSH/inhibin B/AMH — assess spermatogenic potential
6. Olfactory testing — to distinguish Kallmann syndrome
7. Genetic testing — if congenital HH suspected (mutations in GNRH1, FGFR1, PROKR2, KISS1R, etc.)
8. Free testosterone or bioavailable testosterone if SHBG abnormality suspected

Part 3: Treatment — Considering Fertility

If Fertility Is Desired (Current Priority in a 22-Year-Old):

First-line: Gonadotropin Replacement Therapy

• hCG alone often raises testosterone into the normal range and normalizes libido, energy, erections, and muscle mass
• Adding FSH (as recombinant FSH or hMG) is necessary to initiate or restore spermatogenesis
• Spermatogenesis may take 12–24 months to appear; previous testosterone use delays this further
• This is the only reliable pharmaceutical treatment for infertility in HH — Goldman-Cecil Medicine notes that specific gonadotropin treatment is available for the 1–2% of infertile men with gonadotropin insufficiency, while most other causes lack equivalent medical treatment. — Goldman-Cecil Medicine, p. 2736

Second-line alternative (if compliance is an issue): Pulsatile GnRH pump

• Mimics physiological hypothalamic pulsatility (60-min pulses via portable subcutaneous pump)
• Effective when the defect is hypothalamic (Kallmann/idiopathic HH) with an intact pituitary
• Less practical but highly effective for fertility; not widely available

Adjunct: Clomiphene citrate (off-label)

• Selective estrogen receptor modulator (SERM) — blocks estrogen negative feedback at hypothalamus/pituitary → increases endogenous LH/FSH → stimulates testicular testosterone and spermatogenesis
• Useful in functional HH or mild secondary hypogonadism
• Evidence from a 2024 meta-analysis (PMID 37306109) supports estrogen modulation in improving semen parameters in secondary hypogonadism

If Fertility Is NOT a Current Concern:

• Testosterone enanthate or cypionate IM 100–200 mg every 1–2 weeks
• Testosterone gel (transdermal) — daily, mimics diurnal variation
• Goals: normalize testosterone levels, restore libido, morning erections, energy, and muscle mass
• Monitor serum testosterone midway between injections (goal: mid-normal range)
• TRT suppresses LH → testicular atrophy and azoospermia — this must be explained to the patient before initiating

Summary Algorithm

22M, hypogonadal symptoms
        ↓
Morning testosterone × 2 → LOW
LH / FSH → LOW/normal  → Secondary (hypogonadotropic) hypogonadism
        ↓
Prolactin → check (exclude prolactinoma)
MRI pituitary → check for structural lesion
Olfactory testing → Kallmann?
        ↓
FERTILITY DESIRED?
  YES → hCG ± FSH (gonadotropin therapy)
        — Raises testosterone AND enables spermatogenesis
        — Add FSH after 3–6 months if azoospermia persists
  NO  → Testosterone replacement (gel, IM injection)
        — Counsel: causes azoospermia; reversible with switch to gonadotropins

Recent Evidence

• PMID 41206002 (Dwyer & Stamou, J Clin Endocrinol Metab 2026) — Reviews reversal of congenital HH; some patients achieve normal reproductive function with treatment
• PMID 39673783 (J Clin Endocrinol Metab 2025) — Gonadotropin therapy in HH
• PMID 37306109 (Andrology 2024, meta-analysis) — Estrogen modulation (clomiphene/tamoxifen) improves semen parameters in secondary hypogonadism

The New Finding Changes the Diagnosis

Why Gynecomastia Shifts the Diagnosis

"Testosterone is decreased and estradiol is increased, leading to clinical features of undervirilization and gynecomastia. The ratio of estrogens to testosterone determines the degree of feminization in individual cases." — Harrison's Principles of Internal Medicine, 22E

• Damaged Leydig cells → ↓ testosterone
• Despite damage, residual Sertoli cells and Leydig cells continue to aromatize androgens → disproportionately elevated estradiol
• ↑ Estradiol/testosterone ratio → stimulates ductal proliferation in breast tissue = gynecomastia
• Low testosterone also fails to suppress breast growth as it normally would
• Elevated LH/FSH (pituitary sensing low T) → further drives estrogen production peripherally

Revised Diagnosis: Klinefelter Syndrome (47,XXY)

• Small, firm atrophic testes (< 5 mL; the hallmark)
• Long legs relative to trunk (eunuchoid proportions — span > height; pubis-to-floor > pubis-to-crown)
• Female-pattern pubic hair distribution
• Decreased facial, axillary, and body hair

Revised Hormone Profile

This is the opposite of hypogonadotropic hypogonadism — here LH and FSH are elevated because the pituitary is working hard to stimulate failing testes. — Robbins & Kumar Pathologic Basis of Disease, p. 167

Confirming the Diagnosis

1. Karyotype (gold standard) — Classic: 47,XXY (90% of cases); Mosaic: 46,XY/47,XXY (10%)
   • Higher polysomic forms exist: 48,XXXY / 49,XXXXY → more severe phenotype
2. Hormones: ↓ total testosterone, ↑↑ FSH, ↑ LH, ↑ estradiol
3. Semen analysis — azoospermia is the rule in 47,XXY; some sperm may be found in mosaic forms
4. Testicular ultrasound — small, hypoechoic testes; assess for microlithiasis or tumor
5. Bone density (DEXA) — osteoporosis risk from chronic hypogonadism

Pathology of the Testis

"In some patients the testicular tubules are totally atrophied and replaced by pink, hyaline, collagenous 'ghosts.' In others, apparently normal tubules are interspersed with atrophic tubules... Leydig cells appear prominent due to atrophy in the germ cell compartment." — Robbins & Kumar Pathologic Basis of Disease, p. 167

Treatment — Revised for Klinefelter Syndrome

1. Testosterone Replacement Therapy (TRT) — Core Treatment

• Indicated to correct hypogonadism symptoms: libido, erections, energy, muscle mass, mood, bone density
• Formulations: testosterone enanthate/cypionate IM, or testosterone gel (transdermal)
• Goal: mid-normal serum testosterone range
• Benefit: Within months → improved libido, energy, haematocrit; within 6 months → increased muscle mass, decreased fat; bone density improves over 2 years
• Important: TRT will suppress residual spermatogenesis via LH/FSH suppression — fertility must be addressed before starting TRT

2. Fertility — The Critical Point in a 22-Year-Old

Microsurgical Testicular Sperm Extraction (micro-TESE)

"Fertility can be achieved by intracytoplasmic injection of sperm retrieved surgically from the testes of men with Klinefelter syndrome, including some men with the nonmosaic form." — Harrison's 22E, p. 102 (block 44)

• A urologist performs microdissection TESE (mTESE) to locate and extract residual sperm from isolated spermatogenic foci
• Sperm retrieval success rates: ~50% in non-mosaic 47,XXY; higher in mosaic forms
• At age 22, sperm may still be present — retrieval success decreases with age as progressive tubular atrophy continues
• Retrieved sperm are used for intracytoplasmic sperm injection (ICSI) with partner's oocytes

Timing is Critical:

"Although sperm retrieval in adolescence for fertility preservation offers no benefit over harvesting in adulthood, fertility counseling, including the potential for sperm retrieval, should be offered prior to starting testosterone replacement therapy." — Harrison's 22E

3. Gynecomastia Management

• Grade I (small bud, as in this patient): Often improves with TRT as testosterone rises and estradiol/testosterone ratio normalizes
• If persistent or cosmetically distressing after testosterone normalization: subcutaneous mastectomy (the definitive treatment)
• Aromatase inhibitors (anastrozole, letrozole) may reduce estradiol and gynecomastia, but evidence for long-term use in Klinefelter is limited

4. Surveillance (Klinefelter-specific Risks)

Summary

Patchy beard + low libido + no morning erections +
low energy + poor muscle bulk + GYNECOMASTIA
              ↓
KLINEFELTER SYNDROME (47,XXY)
              ↓
Labs: ↓ Testosterone, ↑↑ LH, ↑↑ FSH, ↑ Estradiol
Confirm: Karyotype
              ↓
MANAGEMENT SEQUENCE:
1. Fertility counseling NOW (age 22 — sperm still retrievable)
2. Offer micro-TESE + sperm cryopreservation BEFORE TRT
3. Start TRT (testosterone enanthate/gel) after fertility addressed
4. Monitor and treat gynecomastia
5. Lifelong surveillance for comorbidities